GlassScriptPhysician profile
Terrisha Floyd
NPI 1336851617
$1,968.89
in general payments reported to CMS, 2019-2025
21 companies · $827 in 2025
The $827 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $398 · 2024: $744 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.64 | 2023-2025 | |
| Novo Nordisk INC | $271.49 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $234.37 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $233.40 | 2024-2025 | Symbravo, Sunosi, Auvelity |
| Lilly USA, LLC | $219.07 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $106.55 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $97.22 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.72 | 2023-2024 | Jardiance |
| Almatica Pharma LLC | $40.42 | 2023-2024 | Loreev Xr |
| Xeris Pharmaceuticals, INC. | $38.49 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $38.44 | 2024-2025 | |
| Glaxosmithkline, LLC. | $34.83 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Corium, LLC | $33.40 | 2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.50 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $20.69 | 2024 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $20.16 | 2023 | Vyepti |
| Merck Sharp & Dohme LLC | $19.16 | 2024 | Capvaxive |
| Neos Therapeutics, LP | $18.77 | 2023 | Adzenys Xr-Odt |
| Hikma Pharmaceuticals USA | $16.96 | 2023 | Mitigare, Ryaltris |
| Tris Pharma INC | $15.99 | 2023 | Dyanavel Xr |
| Amgen INC. | $14.62 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrisha Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.